US45257U1088 - Common Stock
Immunome (IMNM) files prospectus for resale of 21.7 million common shares.
Immunome reports Q3 financial results with a GAAP EPS of -$0.36 and revenue of $3.57M.
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Ademi LLP is investigating Immunome (Nasdaq: IMNM) for possible breaches of fiduciary duty and other violations of law in its private placement...
Biopharmaceutical company, Immunome (IMNM) and Morphimmune enter merger agreement, whereby the combined company, which will operate as Immunome and retain the same ticker symbol,...
AbbVie is tapping Immunome to help develop new cancer treatments.
/PRNewswire/ -- AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell...